165 related articles for article (PubMed ID: 22073242)
1. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.
London CA; Bear MD; McCleese J; Foley KP; Paalangara R; Inoue T; Ying W; Barsoum J
PLoS One; 2011; 6(11):e27018. PubMed ID: 22073242
[TBL] [Abstract][Full Text] [Related]
2. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Lin TY; Bear M; Du Z; Foley KP; Ying W; Barsoum J; London C
Exp Hematol; 2008 Oct; 36(10):1266-77. PubMed ID: 18657349
[TBL] [Abstract][Full Text] [Related]
3. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
[TBL] [Abstract][Full Text] [Related]
4. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
[TBL] [Abstract][Full Text] [Related]
5. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
6. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
London CA; Acquaviva J; Smith DL; Sequeira M; Ogawa LS; Gardner HL; Bernabe LF; Bear MD; Bechtel SA; Proia DA
Clin Cancer Res; 2018 Dec; 24(24):6396-6407. PubMed ID: 30171047
[TBL] [Abstract][Full Text] [Related]
7. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells.
Özgür A
J Chemother; 2021 Dec; 33(8):554-563. PubMed ID: 33794753
[TBL] [Abstract][Full Text] [Related]
8. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
Goldman JW; Raju RN; Gordon GA; El-Hariry I; Teofilivici F; Vukovic VM; Bradley R; Karol MD; Chen Y; Guo W; Inoue T; Rosen LS
BMC Cancer; 2013 Mar; 13():152. PubMed ID: 23530663
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Thakur MK; Heilbrun LK; Sheng S; Stein M; Liu G; Antonarakis ES; Vaishampayan U; Dzinic SH; Li X; Freeman S; Smith D; Heath EI
Invest New Drugs; 2016 Feb; 34(1):112-8. PubMed ID: 26581400
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
Goyal L; Wadlow RC; Blaszkowsky LS; Wolpin BM; Abrams TA; McCleary NJ; Sheehan S; Sundaram E; Karol MD; Chen J; Zhu AX
Invest New Drugs; 2015 Feb; 33(1):128-37. PubMed ID: 25248753
[TBL] [Abstract][Full Text] [Related]
12. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
Wang Y; Trepel JB; Neckers LM; Giaccone G
Curr Opin Investig Drugs; 2010 Dec; 11(12):1466-76. PubMed ID: 21154128
[TBL] [Abstract][Full Text] [Related]
13. Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines.
Clemente-Vicario F; Alvarez CE; Rowell JL; Roy S; London CA; Kisseberth WC; Lorch G
PLoS One; 2015; 10(11):e0142007. PubMed ID: 26560147
[TBL] [Abstract][Full Text] [Related]
14. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Jhaveri K; Chandarlapaty S; Lake D; Gilewski T; Robson M; Goldfarb S; Drullinsky P; Sugarman S; Wasserheit-Leiblich C; Fasano J; Moynahan ME; D'Andrea G; Lim K; Reddington L; Haque S; Patil S; Bauman L; Vukovic V; El-Hariry I; Hudis C; Modi S
Clin Breast Cancer; 2014 Jun; 14(3):154-60. PubMed ID: 24512858
[TBL] [Abstract][Full Text] [Related]
15. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
[TBL] [Abstract][Full Text] [Related]
16. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
Choi HK; Lee K
Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.
Proia DA; Foley KP; Korbut T; Sang J; Smith D; Bates RC; Liu Y; Rosenberg AF; Zhou D; Koya K; Barsoum J; Blackman RK
PLoS One; 2011 Apr; 6(4):e18552. PubMed ID: 21533169
[TBL] [Abstract][Full Text] [Related]
18. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
19. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
